A multicenter, open-label study to assess hospitalization rates in adult subjects with schizophrenia treated prospectively for 6 months with Aripiprazole IM Depot compared with 6-month retrospective treatment with oral antipsychotics in a naturalistic community setting in the United States.
Participants must:
be between the ages of 18 and 65 years
have diagnosis of schizophrenia
have 1 inpatient psychiatric hospitalization within past 2 years
have no non-psychiatric hospitalization within past 4 weeks
currently be on oral antipsychotic treatment for past 7 months
Participants cannot:
have a history of head injury or other neurological disorder
have a current or past history of drug dependence
have significant extra pyramidal symptoms (tremors, akathisia) or tardive dyskinesia
Roche Depression Trial
A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to investigate the efficacy and safety of RO4995819 versus placebo, as adjunctive therapy in patients with major depressive disorder having inadequate response to ongoing antidepressant treatment. Protocol # BP25712
Participants must:
be between the ages of 18 and 65 years
have a diagnosis of depression
have an inadequate response to current antidepressant treatment with a selective serotonin reuptake inhibitor (SSRI) or a serotonin norepinephrine reuptake inhibitor (SNRI)
Participants cannot:
currently be receiving treatment with a combination of 3 or more antidepressants
have alcohol and/or substance abuse/dependence during the last 6 months
have a significant ongoing use of high doses of barbiturates, benzodiazepines or other anxiolytic drugs
Forest Depression Trial
A double-blind, placebo-controlled study of cariprazine as adjunctive therapy in major depressive disorder
Participantsmust:
be between the ages of 18 to 65 years
have a diagnosis of depression
have ongoing inadequate response to bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, sertraline, venlafaxine, or vilazodone
Participants cannot:
have any anticonvulsant/mood stabilizer, anxiolytic, benzodiazepine or other anti-depressant agent within one week of entering the study
have alcohol and/or substance abuse/dependence during the last 6 months
have a positive hepatitis C antibody on screening
Alcohol Dependence Trial
This study uses psychotherapy in combination with an experimental mind-altering medication, administered in a clinical setting, to see if this approach promotes recovery from problems with alcohol. Medical and psychiatric evaluations as well as treatment interventions are conducted free of charge.
Participants must:
be between the ages of 25 and 65
be alcohol dependent
be concerned about their drinking
have at least 4 heavy drinking days in the past 30 days
